Is vasoplegic syndrome more prevalent with open-heart procedures compared with isolated on-pump CABG surgery?

[1]  G. Papadopoulos,et al.  Perioperative infusion of low- dose of vasopressin for prevention and management of vasodilatory vasoplegic syndrome in patients undergoing coronary artery bypass grafting-A double-blind randomized study , 2010, Journal of cardiothoracic surgery.

[2]  Gregory W Fischer,et al.  Early On–Cardiopulmonary Bypass Hypotension and Other Factors Associated With Vasoplegic Syndrome , 2009, Circulation.

[3]  Sean M. O'Brien,et al.  Trends in mitral valve surgery in the United States: results from the Society of Thoracic Surgeons Adult Cardiac Surgery Database. , 2009, The Annals of thoracic surgery.

[4]  P. Corso,et al.  Is incidence of postoperative vasoplegic syndrome different between off-pump and on-pump coronary artery bypass grafting surgery? , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[5]  S. Raja,et al.  Should angiotensin converting enzyme inhibitors/angiotensin II receptor antagonists be omitted before cardiac surgery to avoid postoperative vasodilation? , 2008, Interactive cardiovascular and thoracic surgery.

[6]  R. Levine,et al.  Early Repair of Moderate Ischemic Mitral Regurgitation Reverses Left Ventricular Remodeling: A Functional and Molecular Study , 2007, Circulation.

[7]  J. Briegel,et al.  Association between vasopressor dependence and early outcome in patients after cardiac surgery , 2006, Anaesthesia.

[8]  U. Demirkılıç,et al.  Preoperative methylene blue administration in patients at high risk for vasoplegic syndrome during cardiac surgery. , 2005, The Annals of thoracic surgery.

[9]  K. Werdan,et al.  Surgical trauma affects the proinflammatory status after cardiac surgery to a higher degree than cardiopulmonary bypass. , 2005, The Journal of thoracic and cardiovascular surgery.

[10]  M. Enriquez-Sarano,et al.  Quantitative determinants of the outcome of asymptomatic mitral regurgitation. , 2005, The New England journal of medicine.

[11]  R. Levin,et al.  Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. , 2004, The Annals of thoracic surgery.

[12]  O. Ponzio,et al.  Reduction of the inflammatory response following coronary bypass grafting with total minimal extracorporeal circulation. , 2002, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[13]  M. Müllner,et al.  C-reactive protein and mortality in patients with acute aortic disease , 2002, Intensive Care Medicine.

[14]  D. Loisance,et al.  Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function. , 2001, The Annals of thoracic surgery.

[15]  T. Carrel,et al.  Low Systemic Vascular Resistance After Cardiopulmonary Bypass: Incidence, Etiology, and Clinical Importance , 2000, Journal of cardiac surgery.

[16]  M. Underwood,et al.  Inflammatory response after coronary revascularization with or without cardiopulmonary bypass. , 2000, The Annals of thoracic surgery.

[17]  M. Oz,et al.  Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. , 1998, The Journal of thoracic and cardiovascular surgery.

[18]  Kenichi A. Tanaka,et al.  The inflammatory response to cardiopulmonary bypass , 1997 .

[19]  M. Fathi,et al.  Long-term Angiotensin-converting Enzyme Inhibitor Treatment Attenuates Adrenergic Responsiveness without Altering Hemodynamic Control in Patients Undergoing Cardiac Surgery , 1996, Anesthesiology.

[20]  R. McCarthy,et al.  Angiotensin-Converting Enzyme Inhibitors Increase Vasoconstrictor Requirements After Cardiopulmonary Bypass , 1995, Anesthesia and analgesia.

[21]  K. Knobloch,et al.  Methylene blue : The drug of choice for catecholamine-refractory vasoplegia after cardiopulmonary bypass ? , 2002 .